Feed DRMAW
DR

Dermata Therapeutics, Inc. DRMAW · NASDAQ

$0.00 -97.38% (-$0.02)

Summary

52 / 100 · Bulios Score

What speaks for it

  • It has no debt and holds $4.41M in cash.
  • The share price is below the Bulios Fair Price.
  • It bought back its own shares for $367.0 in the last fiscal year, 90% of its market value.

What to watch

  • It passes only 0 of the 9 points of the Piotroski financial health test.
  • Earnings per share swing sharply from year to year.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap

Price against the Bulios Fair Price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Valuation in detail

Is it growing?

It is shrinking

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

There is not enough revenue history yet to say how fast it grows.

Growth in detail

Does it make money?

Over the last 12 months it made a loss of $8.37M.

Profitability in detail

Is it financially healthy?

Yes

It has no debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

No coverage

No analyst covers this stock.

Analysts in detail

What does it earn on?

By product

This revenue breakdown is on the way.

By region

This revenue breakdown is on the way.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.